Yawen L Chiang

US Patent:

20030113296, Jun 19, 2003

Filed:

Dec 19, 2002

Appl. No.:

10/323425

Inventors:

Paul Hallenbeck - Gaithersburg MD, US
Yung-Nien Chang - Cockysville MD, US
Yawen Chiang - Fremont CA, US

International Classification:

A61K048/00
C12N015/86

US Classification:

424/093200, 435/456000, 435/320100

Abstract:

The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.

US Patent:

20030118570, Jun 26, 2003

Filed:

Dec 19, 2002

Appl. No.:

10/323955

Inventors:

Paul Hallenbeck - Gaithersburg MD, US
Yung-Nien Chang - Cockysville MD, US
Yawen Chiang - Fremont CA, US

International Classification:

A61K048/00
C12N015/86
C12N005/08

US Classification:

424/093210, 435/456000, 435/320100, 435/366000

Abstract:

The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.

US Patent:

20030129175, Jul 10, 2003

Filed:

Dec 19, 2002

Appl. No.:

10/323984

Inventors:

Paul Hallenbeck - Gaithersburg MD, US
Yung-Nien Chang - Cockysville MD, US
Yawen Chiang - Fremont CA, US

International Classification:

A61K048/00
C12N015/86
C12N005/08

US Classification:

424/093210, 435/320100, 435/366000, 435/456000

Abstract:

The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.